Citi Starts Sana Biotechnology (SANA) at Buy, 'Hypoimmune Platform is a Potential Game Changer for Allogeneic Cell Therapy'
Tweet Send to a Friend
(Updated - September 5, 2023 4:31 AM EDT)
Citi analyst Samantha Semenkow initiates coverage on Sana Biotechnology (NASDAQ: SANA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Citi analyst Samantha Semenkow initiates coverage on Sana Biotechnology (NASDAQ: SANA) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
